Yingjie Hu - Publications

Rational design of an NLRP3 inhibitor with superior efficacy and safety for gout therapy.

Journal: European journal of medicinal chemistry

Published: October 30, 2025

Comparison between sub-lobar resection and lobar resection for clinical stage IA (tumor size ≤ 2 cm) lung invasive mucinous adenocarcinoma with tumor spread through air spaces: A multi-center real-world study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 18, 2025

Hit to lead optimization of isopentenyl chalcones as novel MTHFD2 inhibitors for cancer treatment: design, synthesis, in-vitro, in-vivo and in-silico studies.

Journal: European journal of medicinal chemistry

Published: March 12, 2025

Early outcomes of minimally invasive surgery versus thoracotomy for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a multi-center real-world study.

Journal: International journal of surgery (London, England)

Published: April 18, 2024

Total synthesis/semi-synthesis of natural isopentenyl flavonoids with inhibitory activity on NLRP3 inflammasome.

Journal: Bioorganic & medicinal chemistry letters

Published: March 12, 2024

Quality of lymph node dissection and early recurrence in robotic versus thoracoscopic lobectomy for stage N1-2 non-small cell lung cancer: Eleven-year real-world data from a high-volume center.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: March 07, 2024